Remote Monitoring in Patients With Heart Failure
Remote Monitoring in Patients With Heart Failure
This study is a prospective cohort study with consecutive enrollment of newly diagnosed heart
 failure patients, investigating the prevalence and types of arrhythmias in this high-risk
 population using non-invasive remote monitoring with the Coala Heart Monitor. Participants
 are scheduled to use the Coala Heart Monitor twice daily or during symptoms (e.g. syncope,
 presyncope, palpitations, chest discomfort, or shortness of breath) to record a thumb and
 chest ECG over 3 months. Patient compliance with the recordings, self-reported health,
 response to technology, and experience using the device will additionally be assessed by
 self-developed questionnaires and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3
 months.
Inclusion Criteria:

 -  Owns or has access to a smartphone

 -  Newly diagnosed moderate to severe heart failure (NYHA II-IV and left ventricular
 ejection fraction ≤ 40%)

 Exclusion Criteria:

 -  Earlier atrial fibrillation/atrial flutter with indication for oral anticoagulant
 (OAC) treatment

 -  Pacemaker

 -  Cardiac resynchronization device

 -  Indications for OAC treatment (also low molecular weight heparin) due to atrial
 arrhythmias, mechanical heart valve, deep vein thrombosis, or pulmonary embolism.

 -  Expected survival ≤ 6 months

 -  Absolute contraindications for starting OAC treatment